key: cord-0885837-xuspbxfj authors: Farouq, Mohammed A.H.; Al Qaraghuli, Mohammed M.; Kubiak-Ossowska, Karina; Ferro, Valerie A.; Mulheran, Paul A. title: Biomolecular interactions with nanoparticles: Applications for COVID-19 date: 2021-04-23 journal: Curr Opin Colloid Interface Sci DOI: 10.1016/j.cocis.2021.101461 sha: a8be04f825b853de310e9222925013634915fb9c doc_id: 885837 cord_uid: xuspbxfj Nanoparticles are small particles sized 1 to 100 nm, which have a large surface to volume ratio, allowing efficient adsorption of drugs, proteins and other chemical compounds. Consequently, functionalised nanoparticles have potential diagnostic and therapeutic applications. A variety of nanoparticles have been studied, including those constructed from inorganic materials, bio-polymers, and lipids. In this review, we focus on recent work targeting the SARS-CoV-2 virus that causes COVID-19. Understanding the interactions between coronavirus-specific proteins (such as the spike protein and its host cell receptor ACE2) with different nanoparticles paves the way to the development of new therapeutics and diagnostics that are urgently needed for the fight against COVID-19, and indeed for related future viral threats that may emerge. ABSTRACT 23 Nanoparticles are small particles sized 1 to 100 nm, which have a large surface to 24 volume ratio, allowing efficient adsorption of drugs, proteins and other chemical 25 compounds. Consequently, functionalised nanoparticles have potential diagnostic and 26 therapeutic applications. A variety of nanoparticles have been studied, including those 27 constructed from inorganic materials, bio-polymers, and lipids. In this review, we focus 28 on recent work targeting the SARS-CoV-2 virus that causes the interactions between coronavirus-specific proteins (such as the spike protein and its Nanoparticles (NPs) are very small materials with a dimension between 1 and 100 nm. 50 Their key physicochemical properties include a high surface area to volume ratio, 51 solubility, surface topology/morphology and controllable aggregation, making them 52 suitable for application in a variety of commercial and domestic sectors including 53 electronics, catalysis, environment, imaging, energy, automotive and healthcare (1). 54 There are various types of NPs, from inorganic materials such as gold, silica, graphene, 55 and iron oxide, to organic materials where the main groups include liposomes, micelles, 56 protein/peptides, and dendrimers. They are particularly useful in healthcare 57 applications, mainly due to their high capacity for adsorbing biomolecules (2) . 58 Pharmaceutical nanotechnology is the development of therapeutic materials and 59 devices at a nanometre scale, and there are several advantages to exploiting NPs in 60 drug delivery. These include, but are not limited to: (i) improvement in the solubility of 61 certain drugs; (ii) controlled, sustained release of drugs for a long-term effect; (iii) 62 reduction of the side effects of some drugs; (iv) targeting of specific cells; (v) 63 administration routes; and (vi) delivery of drugs in a secure manner, so that they are 64 protected from degradation in the body and can effectively reach the target cells intact 65 (3). NPs can display efficient adsorption of proteins, drugs molecules, and a variety of 66 other chemical compounds. Therefore, NPs can carry a varied cargo load (4), making 67 them efficient not only for drug delivery, but also diagnostic and therapeutic 68 applications. In this review, we explore how NPs have been used to develop approaches to tackling 70 COVID-19, focusing on the interactions between NPs and adsorption of molecules such 71 as proteins and drugs. We start with a brief overview of NP properties and their potential 72 anti-viral applications. We then review the SARS coronavirus (SARS-CoV-2) that 73 causes COVID-19 and its proteins that are the targets for new technologies, before 74 turning to the various types of NPs that can be used as the basis for these technologies. 75 J o u r n a l P r e -p r o o f Alternative approaches to treating COVID-19, for example by repurposing drugs that 76 were previously successful against other viruses, is discussed, followed by an overview 77 of developments in diagnostics. We finish the review with a summary and forward look 78 as to how understanding the interactions between the different molecules and NPs 79 could be used to rationally design new technologies to help tackle this pandemic and 80 future coronavirus disease. The key properties of NPs (Figure 1 ) make them ideal for a variety of effective systems. The biodegradation of NPs also requires attention, as uniform bio-distribution kinetics 106 and sustained drug release are key elements in the drug design process. Absorption, 107 distribution, metabolism and excretion are pharmacokinetic features linking directly to 108 the nature and profile of these systems, and it is therefore crucial to account for all 109 these factors when designing a nanoparticulate therapy (10). This is due to their high biocompatibility, low toxicity, ability to cross membranes and 134 seamless integration with hydrophobic/hydrophilic drugs. The S protein is an important therapeutic and diagnostic target, as it is responsible for 177 entry into and infiltration of the host cell. It is a homotrimer with two domains, S1 and S2 178 on each monomer. Analysis of these monomers shows they are highly glycosylated 179 (26), protecting the protein from the biological environment and allowing evasion from 180 the host immune system. The S1 subunit contains the receptor binding domain (RBD) 181 that binds to the peptidase domain of angiotensin-converting enzyme 2 (ACE2) ( Figure 182 3), a cellular receptor expressed on several cell types in human tissues, and this allows 183 entry of SARS-CoV-2 into the cell (27). Upon cell entry, two ORFs, 1a and 1b, translate to two polypeptides (1a and 1ab) and 185 this further encodes two proteases, the main protease (M pro ), also known as the 186 chymotrypsin-like cysteine protease (3CL pro ), and papain-like protease (PL pro ) (28). These represent significant drug targets, since inhibition of these will stop production of 188 proteins that are critical to viral transcription and replication (29-31). The S1 subunit allows entry of the virus into the host cell, and inhibition of this will block 190 the protein from interacting with the ACE2 receptor (32). For example, immunoadhesins Therefore, SR-B1 could also potentially be a target for therapeutic designs. Patel et al. 203 have also suggested HE as a target (36) to inhibit the virus invasion mechanism. The residues responsible for the interaction between the S protein and the ACE2 205 receptor have been investigated by Veeramachaneni et al. (37) . This information is 206 important for designing any medicine, since the residues required for interaction with the 207 target should remain free to bind to the therapeutic molecule, to allow effective 208 inhibition. Their analysis has identified the key residues that interact with the ACE2 Inset shows key interacting residues between the ACE2 receptor. The crystal structure 213 was obtained from the Protein Databank (PDB entry 6M0J (38)). The crystal structure 214 was viewed and analysed using VMD (Visual Molecular Dynamics 1.9.1). The potential of NPs for the treatment of COVID-19 is promising due to their various 218 properties. Iron oxide NPs, which have previously been investigated for their anti-viral 219 activity, were simulated for their interaction with the RBD of the S1 subunit (39). It was 220 found that a model Fe 3 O 4 NP forms a stable complex with the protein, interacting 221 through several hydrophobic interactions primarily with residues Leu455, Ser494 and 222 Phe497. Therefore, these NPs, which are currently an approved treatment for anaemia, 223 could be repurposed to treat . biomedically relevant surfaces has been examined computationally, and it was found 230 that the RBD of the S protein interacts with negatively charged silica surfaces so that 231 the epitope (part of the antigen molecule, RBD in this instance, to which an antibody 232 binds) is exposed. A model gold surface has also shown good interaction with the 233 protein (42). The use of charged or hydrophobic surfaces in developing therapies may 234 therefore be significant as they show good adsorption (42). advantages, repurposing a drug must be approached with caution as some drugs can 303 cause poly-pharmacological side effects, and intellectual property issues may arise (53). As already discussed, the ACE2 receptor, expressed on many cell types, is key to the 305 initial cellular entry by SARS-CoV-2. Therefore, Khelfaoui (54) used molecular docking 306 combined with MD simulations to study drugs similar in structure to chloroquine and 307 hydroxychloroquine, which are both approved medicines, aiming to block the ACE2 308 receptor. The studies were performed using two structures, the ACE2 receptor and Table 1 . These could then be used in isolation or conjugated to 314 NPs to enhance their properties. The applications of natural compounds against COVID-19 are summarised in Table 2 . The versatility of natural compounds may allow for easier interaction with NPs 337 compared to pre-existing drugs. Melatonin (76) The drug repurposing approach can also be used to analyse synthetic chemical 342 compounds that might prove to be effective anti-virals. This can be achieved by 343 screening a database of small molecules against viral drug targets to identify molecules 344 with possible anti-viral activity, or by developing chemical compounds in-house. Promising synthetic chemicals which have been investigated against COVID-19 are 346 summarised in Table 3 . have been reported so far, this technology has the potential to offer a better and Nanoparticles: Properties, applications and toxicities Rational engineering of physicochemical properties of nanomaterials for 422 biomedical applications with nanotoxicological perspectives The potential advantages of nanoparticle drug 425 delivery systems in chemotherapy of tuberculosis. American journal of respiratory and critical care 426 medicine Nanoparticles in modern medicine: state of the art and future challenges. 429 International journal of nanomedicine Reactive Oxygen Species-Related Nanoparticle 432 Toxicity in the Biomedical Field Chemical Properties of Nanoparticles on Their Intracellular Uptake Cloaking nanoparticles with protein 439 corona shield for targeted drug delivery Toward a molecular understanding of nanoparticle-protein interactions A systematic review on use of aminoquinolines for the 448 therapeutic management of COVID-19: Efficacy, safety and clinical trials Porous gold nanoparticles for attenuating 452 infectivity of influenza A virus Presentation of HIV-1 Envelope Trimers on the 455 Surface of Silica Nanoparticles Abd El-Hafeiz YGM. Inhibitory effect of silver 460 nanoparticles on bovine herpesvirus-1 Silver Nanoparticles with Bronchodilators through Nebulisation to Treat Covid 19 464 Patients The Lord of the 466 NanoRings: Cyclodextrins and the battle against SARS-CoV-2 This article looks at the various properties of cyclodextrins which make these nanoparticles suitable for a 469 variety of applications in treating COVID-19. This includes acting as encapsulating agents for other drugs 470 used to treat COVID-19, as adjuvants to stabilise molecules involved in infection and use as adjuvants in 471 vaccines Can Nanotechnology 473 and Materials Science Help the Fight against SARS-CoV-2? Multivalent nanomedicines to treat COVID-19: A slow train coming. 476 Nano Today Mechanics of receptor-mediated endocytosis. Proceedings of the 479 National Academy of Sciences of the United States of America Nanotheranostics against COVID-19: From multivalent to immune-targeted 482 materials Pathological inflammation in patients with COVID-19: a key role for 485 monocytes and macrophages SARS-CoV-2 in environmental 488 perspective: Occurrence, persistence, surveillance, inactivation and challenges This is an interesting article because it discusses the transmission routes of SARS-CoV-2. As well as the 492 common transmission route by droplets, this article suggests the faecal-oral route as a possible source 493 of SARS-CoV-2 transmission, and suggests strategies to combat the enteric virus Histopathological 496 findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. The Lancet 497 Microbe A new coronavirus associated with 500 human respiratory disease in China Coronavirus envelope protein: current knowledge Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly 595 people shows Self-amplifying RNA SARS-CoV-602 2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice A perspective 606 on potential antibody-dependent enhancement of SARS-CoV-2 Secretory IgA's complex roles in immunity and mucosal 612 homeostasis in the gut Drug repurposing: progress, 615 challenges and recommendations Molecular docking, molecular dynamics simulations and 618 reactivity, studies on approved drugs library targeting ACE2 and SARS-CoV-2 binding with ACE2 Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-623 approved inhibitors of SARS-CoV-2 main protease 3CLpro Remdesivir-bound and ligand-free 627 simulations reveal the probable mechanism of inhibiting the RNA dependent RNA polymerase of severe 628 acute respiratory syndrome coronavirus 2 Structural insight to 631 hydroxychloroquine-3C-like proteinase complexation from SARS-CoV-2: inhibitor modelling study 632 through molecular docking and MD-simulation study Interaction of 636 hydroxychloroquine with SARS-CoV2 functional proteins using all-atoms non-equilibrium alchemical 637 simulations Anti-HCV and anti-malaria agent, potential candidates to repurpose for 640 coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study. 641 Life Sciences Comparative 644 molecular investigation of the potential inhibitors against SARS-CoV-2 main protease: a molecular 645 docking study Combined drug repurposing and 648 virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-649 Journal of biomolecular structure & dynamics Molecular docking, validation, dynamics 652 simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-653 protease Molecular docking and simulation studies on 656 SARS-CoV-2 Mpro reveals Mitoxantrone, Leucovorin, Birinapant, and Dynasore as potent drugs against 657 COVID-19 Understanding the binding 660 affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different 661 temperatures In silico prediction of potential inhibitors for the main protease of 664 SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing Molecular docking 668 and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study Possibility of HIV-1 protease inhibitors-clinical trial drugs 672 as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and 673 binding free energy simulation study Delivering 676 natural products and biotherapeutics to improve drug efficacy Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2 This article looks at peptide inhibitors to be used against the RBD of SARS-CoV-2, preventing virus action The inhibitors were formed by a bundle of alpha helices found in the RBD Application prospect of polysaccharides in the development of 685 anti-novel coronavirus drugs and vaccines The antiviral activity of polysaccharides and their derivatives Antiviral 692 Activity of Chitosan Nanoparticles Encapsulating Curcumin Against Hepatitis C Virus Genotype 4a in 693 Human Hepatoma Cell Lines Evaluation of green tea polyphenols as novel 696 corona virus (SARS CoV-2) main protease (Mpro) inhibitors -an in silico docking and molecular dynamics 697 simulation study Screening of plant-based natural compounds as a potential COVID-19 700 main protease inhibitor: an in silico docking and molecular dynamics simulation approach The potential role of procyanidin as a 704 therapeutic agent against SARS-CoV-2: a text mining, molecular docking and molecular dynamics 705 simulation approach Structural and physico-708 chemical evaluation of melatonin and its solution-state excited properties, with emphasis on its binding 709 with novel coronavirus proteins Identification of 712 potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies Molecular modelling 716 investigation for drugs and nutraceuticals against protease of SARS-CoV-2 Bacterial protein azurin 720 and derived peptides as potential anti-SARS-CoV-2 agents: insights from molecular docking and 721 molecular dynamics simulations Human Intestinal Defensin 5 Inhibits SARS-CoV-2 724 Invasion by Cloaking ACE2 This article suggests the Human Intestinal Defensin 5 (HD5), an antibiotic enteric peptide, can effectively 727 mask key interaction sites on the ACE2 receptor protein. These sites, key amino acid residues, are 728 important for the S protein to bind and allow viral entry and infection Silico De Novo Curcuminoid Derivatives From the Compound Library of Natural Products Research Laboratories Inhibit COVID-19 732 3CLpro Activity Computational screening of antagonists against the SARS-CoV-2 735 (COVID-19) coronavirus by molecular docking Chemical-informatics approach to COVID-19 drug discovery Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as 740 papain-like protease (PLpro) inhibitors Identification of potential 743 anti-TMPRSS2 natural products through homology modelling, virtual screening and molecular dynamics 744 simulation studies Virtual screening, ADMET prediction and 747 dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2 Promising inhibitors 751 of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular 752 dynamics simulation Interaction of the 755 prototypical α-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: Molecular 756 dynamic simulations highlight the stability of the ligand-protein complex. Computational biology and 757 chemistry Crystal structure of SARS-CoV-2 760 main protease provides a basis for design of improved α-ketoamide inhibitors Elucidating biophysical basis of binding of inhibitors 764 to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations Current trends in nanobiosensor technology. Wiley interdisciplinary 768 reviews Nanomedicine and nanobiotechnology Dual-Functional Plasmonic Photothermal 771 Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection This study looks at the development of a dual-functional plasmonic photothermal biosensor which can 775 detect viral sequences from SARS-CoV-2. The sensor gave a label-free, real time detection of RdRp This represents a promising simple, yet rapid diagnostic tool Polymerase Chain 779 Reaction and Its Application in the Diagnosis of Infectious Keratitis. Medical hypothesis, discovery & 780 innovation ophthalmology journal Rapid and Sensitive Detection of Using Lanthanide-Doped Nanoparticles-Based Lateral Flow Immunoassay Biosensor and 787 molecular-based methods for the detection of human coronaviruses: A review. Molecular and Cellular 788 Probes Bovine Serum Albumin Adsorption 791 at a Silica Surface Explored by Simulation and Experiment Rationalising drug delivery using nanoparticles: a combined simulation and immunology study of GnRH 796 adsorbed to silica nanoparticles ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work ☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests